8-K: XTL Acquires Beyond Air's NeuroNOS, Targets Autism Market

XTL Biopharmaceuticals has acquired an 85% stake in Beyond Air's NeuroNOS subsidiary, gaining a foothold in the autism therapeutics market with Nobel Prize-winning scientific leadership.

Summary

• XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) has entered into a binding agreement to acquire an 85% ownership interest in NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ: XAIR).
• NeuroNOS is a biotechnology company focused on pioneering disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder (ASD) and neuro-oncology, specifically related to nitric oxide dysregulation.
• Beyond Air will receive consideration including 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million.
• The milestone payments include up to $5.5 million for clinical development from Phase 1 through NDA submission and up to $26 million upon achieving product sales targets.
• The acquisition positions XTL as a major player in the rapidly expanding autism therapeutics market, addressing a critical unmet medical need where no FDA-approved disease-modifying therapies currently exist.
• NeuroNOS's scientific leadership includes founder Professor Haitham Amal and two Nobel Laureates in Chemistry, Professor Dan Shechtman and Professor Roger Kornberg.
• NeuroNOS has secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome (a rare genetic disorder with strong autism correlation) and Glioblastoma (an aggressive form of brain cancer).

Sentiment

Score: 8

Explanation: The announcement is highly positive for both Beyond Air and XTL. Beyond Air is monetizing a valuable asset while retaining significant upside through an equity stake and milestone payments. XTL is gaining a promising pipeline in a high-need market with strong scientific backing and regulatory designations. The overall tone is optimistic, highlighting unmet medical needs and groundbreaking science.

Positives

• Beyond Air receives significant consideration, including a substantial equity stake in XTL (19.9%), $1 million in cash, and potential milestone payments up to $32.5 million, unlocking value for its shareholders.
• The transaction validates NeuroNOS's groundbreaking science and provides a dedicated public platform with resources and focus to advance its pipeline in autism and neuro-oncology.
• NeuroNOS's platform targets the core pathophysiology of autism, addressing a critical unmet medical need with no existing FDA-approved disease-modifying therapies.
• The scientific team boasts 'unmatched scientific firepower,' including Nobel Laureates and a leading autism researcher, enhancing credibility and potential for innovation.
• FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma provide significant benefits, including seven years of market exclusivity upon approval, tax credits, and expedited regulatory review.
• The U.S. administration has recognized the urgency of autism research, allocating $50 million in new NIH funding, signaling a favorable shift in regulatory priorities and resource allocation.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
• Risks include those related to capital raising, clinical trial timing and results, regulatory approval processes, intellectual property protection, market competition, and other factors described in XTL's SEC filings.
• The Company undertakes no obligation to update these forward-looking statements except as required by law.

Future Outlook

The companies are in the process of entering into definitive agreements, which will be filed once available. Both Beyond Air and XTL are dedicated to bringing the NeuroNOS product for the treatment of autism to market as soon as possible. XTL aims to advance these programs with urgency and rigor, while Beyond Air expects the transaction to create meaningful value for its shareholders and enable NeuroNOS's pipeline to advance with dedicated focus and funding.

Management Comments

• "We are extremely excited to enter the autism field, which represents one of the most significant unmet medical needs today. With an extraordinary scientific team that includes two Nobel Laureates and Professor Haitham Amal from Harvard and Hebrew University, we have assembled the expertise needed to make a real difference. This acquisition positions XTL at the forefront of autism therapeutics, and we are committed to advancing these programs with the urgency and rigor they deserve." Noam Band, CEO of XTL Biopharmaceuticals.
• "This transaction represents a pivotal moment for NeuroNOS, validating the groundbreaking science we've been developing and also providing the potential to create meaningful value for our shareholders by enabling NeuroNOS's pipeline to advance with dedicated focus and funding. We are proud to become significant shareholders in XTL and believe this focused public platform provides NeuroNOS with the resources and commitment needed to advance these critical programs. What began as a subsidiary of Beyond Air is now positioned to become a standalone engine for innovation in autism and neuro-oncology, and we remain deeply committed to this mission as invested partners." Steve Lisi, Chairman and CEO of Beyond Air Inc.

Industry Context

This acquisition positions XTL as a new player in the rapidly expanding autism therapeutics market, which is characterized by a critical unmet need for disease-modifying therapies. The market currently lacks FDA-approved treatments that address the underlying neurobiological mechanisms of autism, with existing options primarily managing behavioral symptoms. The U.S. government's recent emphasis on autism research and allocation of $50 million in new NIH funding signals a fundamental shift in regulatory priorities and resource allocation, creating a more favorable environment for companies like NeuroNOS. The entry of a platform targeting core biology, backed by Nobel-Prize winning scientists, could disrupt the current landscape dominated by symptomatic treatments.

Comparison to Industry Standards

• NeuroNOS's scientific leadership, including two Nobel Laureates and Professor Haitham Amal, is described as 'unmatched scientific firepower' compared to competitors in the autism therapeutics space.
• The platform targets the core biology of autism, unlike current industry standards that primarily offer symptomatic relief, addressing a critical gap where 'zero FDA-approved disease-modifying therapies exist.'
• The securing of FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma provides significant regulatory advantages and market exclusivity, a competitive edge in the drug development industry.

Stakeholder Impact

• Shareholders (Beyond Air): Potential for significant value creation through cash, equity in XTL, and milestone payments, while retaining exposure to NeuroNOS's success.
• Shareholders (XTL): Gaining a promising new pipeline and market entry into autism therapeutics, potentially increasing company value and market position.
• Patients/Families (Autism/Neuro-oncology): Potential for development of disease-modifying therapies for highly underserved conditions, offering hope for improved outcomes.
• Employees (NeuroNOS): The subsidiary will now serve as XTL's flagship platform, suggesting continued or enhanced focus and resources for its team.

Next Steps

• Beyond Air and XTL are in the process of entering into definitive agreements.
• Definitive agreements will be filed by Beyond Air in a Current Report on Form 8-K or its Annual Report on Form 10-K, once available.
• Both companies are dedicated to bringing the NeuroNOS product for the treatment of autism to market as soon as possible.
• XTL is committed to advancing these programs with urgency and rigor.

Key Dates

Recommendation

This transaction is highly strategic and value-accretive. For XTL, it represents a 'strong buy' opportunity as it gains immediate entry into the massive and critically underserved autism therapeutics market with a scientifically validated platform, Nobel Prize-winning leadership, and valuable FDA Orphan Drug Designations. This fundamentally transforms XTL's strategic direction and growth potential. For Beyond Air, the transaction is a positive strategic move, monetizing a significant portion of its NeuroNOS subsidiary, providing cash, a substantial equity stake in XTL, and potential milestone payments, while allowing Beyond Air to focus on its core nitric oxide platform. This unlocks value for Beyond Air shareholders and provides continued exposure to NeuroNOS's success.

Keywords

Autism Spectrum Disorder, Neuro-oncology, Nitric Oxide, NeuroNOS, Beyond Air, XTL Biopharmaceuticals, Acquisition, Biotechnology, Orphan Drug Designation, Phelan-McDermid Syndrome, Glioblastoma, Therapeutics, Disease-modifying, SEC Filing, 8-K